Lexeo Therapeutics

Contributing Author

Recent Articles by Lexeo Therapeutics

Aug-12	Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights LXEO GlobeNewswire
Aug-05	Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy LXEO GlobeNewswire
Jun-17	Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia LXEO GlobeNewswire
Jun-15	Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia LXEO +6.41% GlobeNewswire
May-19	Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference LXEO GlobeNewswire
May-11	Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights LXEO GlobeNewswire
Apr-27	Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting LXEO GlobeNewswire
Mar-30	Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights LXEO LXEO +8.92% GlobeNewswire
Mar-03	Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference LXEO GlobeNewswire
Feb-05	Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February LXEO -5.23% GlobeNewswire
Jan-27	Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics LXEO GlobeNewswire
Jan-12	Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy LXEO -22.96% GlobeNewswire
Jan-08	Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy LXEO -5.49% GlobeNewswire
Dec-22	Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference LXEO GlobeNewswire
Dec-04	Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum LXEO GlobeNewswire
Nov-05	Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights LXEO GlobeNewswire
Oct-20	Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering LXEO GlobeNewswire
Oct-16	Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement LXEO +9.24% GlobeNewswire
Oct-16	Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants LXEO LXEO +9.24% GlobeNewswire
Oct-07	Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy LXEO +28.90% GlobeNewswire
Aug-14	Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights LXEO GlobeNewswire
Jul-07	Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia LXEO GlobeNewswire
Jun-24	Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics LXEO +6.31% GlobeNewswire
May-27	Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases LXEO GlobeNewswire
May-12	Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights LXEO GlobeNewswire
May-01	Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting LXEO +19.85% GlobeNewswire

Lexeo Therapeutics

Recent Articles by Lexeo Therapeutics

Upgrade your Finviz experience